Jacobs Levy Equity Management’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Jacobs Levy Equity Management’s Portfolio ANTH Stock Details ANTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-10,272	Closed	-$254K	–	1209
2016 Q2	$254K	Buy	10,272 +1,734	+20%	+$49K	0.01%	935
2016 Q1	$247K	Buy	8,538 +6,725	+371%	+$182K	0.01%	925
2015 Q4	$67K	Sell	1,813 -600	-25%	-$26.5K	﹤0.01%	769
2015 Q3	$118K	Sell	2,413 -2,337	-49%	-$163K	﹤0.01%	750
2015 Q2	$328K	Sell	4,750 -313	-6%	-$14.5K	0.01%	634
2015 Q1	$181K	Sell	5,063 -787	-13%	-$23.3K	﹤0.01%	713
2014 Q4	$74K	Sell	5,850 -4,880	-45%	-$70.9K	﹤0.01%	792
2014 Q3	$165K	Buy	10,730 +9,000	+520%	+$189K	﹤0.01%	768
2014 Q2	$47K	Sell	1,730 -95	-5%	-$2.35K	﹤0.01%	815
2014 Q1	$49K	Buy	+1,825	New	+$46.3K	﹤0.01%	871
2013 Q4	–	Sell	-4,408	Closed	-$142K	–	1084
2013 Q3	$142K	Buy	+4,408	New	+$137K	﹤0.01%	878

Other funds holding ANTH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PAI

ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jacobs Levy Equity Management's ANTH Position: Q3 2016 in Review

Jacobs Levy Equity Management sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q3 2016, closing a stake of 10,272 shares — an estimated $254K sold.

Jacobs Levy Equity Management first reported a position in ANTH in Q3 2013 and held it in 11 quarters. The position peaked at $328K in Q2 2015. 72 funds tracked by Wall St. Rank hold ANTH as of Q3 2016.

Jacobs Levy Equity Management reported no remaining Anthera Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
Jacobs Levy Equity Management sold 10,272 Anthera Pharmaceuticals, Inc. shares in Q3 2016, an estimated $254K.
Jacobs Levy Equity Management first reported a position in Anthera Pharmaceuticals, Inc. in Q3 2013 and held it in 11 quarters.
Jacobs Levy Equity Management's Anthera Pharmaceuticals, Inc. position peaked at $328K in Q2 2015.
72 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q3 2016.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2016, filed 14 Nov 2016.